Translation of Immediate Report Filed by Elron Electronic Industries Ltd onMarch, 28, 2024 with the Israeli Securities Authority The Company announced that the.
Bioventus to exercise option to buy CartiHeal for $500m globes.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globes.co.il Daily Mail and Mail on Sunday newspapers.
CartiHeal succeeds in clinical trial for cartilage treatment
CartiHeal is on a Breakthrough Therapy fast track for FDA approval, and US company Bioventus has an option to acquire it.
Israeli company CartiHeal has announced success in a clinical trial of its treatment for knee cartilage damaged either by injury or by arthritis. The company reported that its cartilage substitute product was more successful than the currently used treatments. The trial involved 251 patients, and was conducted over two years.
Among the investors in CartiHeal are Elron Electronic Industries Ltd. (TASE: ELRN), with a holding of 27%, Accelmed, headed by Dr. Uri Geiger, venture capital firms aMoon, Peregrine Ventures, Johnson & Johnson Innovation, and Access Medical. The company s technology originated at Ben Gurion University of the Negev, which also holds shares in the company through its technology transfer arm. The company was founded in the Incentive technology incubator, owned by Peregrine Ventures.